ECSP14011792A - Inhibidores de iap - Google Patents

Inhibidores de iap

Info

Publication number
ECSP14011792A
ECSP14011792A ECIEPI201411792A ECPI201411792A ECSP14011792A EC SP14011792 A ECSP14011792 A EC SP14011792A EC IEPI201411792 A ECIEPI201411792 A EC IEPI201411792A EC PI201411792 A ECPI201411792 A EC PI201411792A EC SP14011792 A ECSP14011792 A EC SP14011792A
Authority
EC
Ecuador
Prior art keywords
iap inhibitors
inhibitors
iap
useful
general formula
Prior art date
Application number
ECIEPI201411792A
Other languages
English (en)
Spanish (es)
Inventor
Lewis J Gazzard
Vickie Hsiao-Wei Tsui
John A Flygare
Frederick Cohen
Original Assignee
Genentech Inc
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Curis Inc filed Critical Genentech Inc
Publication of ECSP14011792A publication Critical patent/ECSP14011792A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ECIEPI201411792A 2012-01-03 2014-07-31 Inhibidores de iap ECSP14011792A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261582760P 2012-01-03 2012-01-03

Publications (1)

Publication Number Publication Date
ECSP14011792A true ECSP14011792A (es) 2015-12-31

Family

ID=48695302

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201411792A ECSP14011792A (es) 2012-01-03 2014-07-31 Inhibidores de iap

Country Status (41)

Country Link
US (6) US8716236B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP2800749B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP5747137B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (3) KR101917992B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN107915728B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR089623A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013202780B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014016637B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2861637C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2014001770A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO7020915A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR20140367A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1118371T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK3133073T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP14011792A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2672809T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1203949A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (2) HRP20161381T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HUE037760T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL242314A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (2) LT2800749T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA35895B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (2) ME02526B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX336294B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY178390A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO2755614T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ627480A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20142182A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (2) PH12014501534A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL3133073T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT2800749T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (2) RS57438B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (2) RU2593259C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201403784QA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI2800749T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SM (2) SMT201800352T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR201808088T4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI503318B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA114417C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013103703A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201405535B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2755614T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2012-01-03 2018-03-31
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (zh) * 2017-10-25 2022-04-29 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用
CA3082437A1 (en) * 2017-11-13 2019-05-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Smac mimetics used as iap inhibitors and use thereof
EP3831811A4 (en) 2018-07-31 2022-04-20 Fimecs, Inc. HETEROCYCLIC COMPOUND
US20220402935A1 (en) 2019-07-31 2022-12-22 Fimecs, Inc. Heterocyclic compound
WO2021110011A1 (en) * 2019-12-02 2021-06-10 Ascentage Pharma (Suzhou) Co., Ltd. Combination of iap inhibitors and parp or mek inhibitors or other chemotherapeutic agents
EP4093394A1 (en) 2020-01-20 2022-11-30 Astrazeneca AB Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
MX2024004848A (es) 2021-10-22 2024-07-15 Univ Houston System Metodos y composiciones para el tratamiento de lesiones inflamatorias cronicas, metaplasias, displasia y canceres de tejidos epiteliales.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
EP0975608B1 (en) 1997-04-15 2005-06-15 Genentech, Inc. Halo-alkoxycarbonyl prodrugs
ZA200700032B (en) * 2004-07-02 2008-05-28 Genentech Inc Inhibitors of IAP
MX2007007195A (es) * 2004-12-20 2007-10-08 Genentech Inc Inhibidores de pirrolidina de iap.
MX2009003834A (es) 2006-10-12 2009-04-22 Novartis Ag Derivados de pirrolidina como inhibidores de iap.
PE20090211A1 (es) 2007-04-30 2009-04-02 Genentech Inc Inhibidores de las iap
NO2755614T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2012-01-03 2018-03-31
USD690416S1 (en) 2012-12-12 2013-09-24 Pharmajet, Inc. Needle-free syringe

Also Published As

Publication number Publication date
CO7020915A2 (es) 2014-08-11
NZ627480A (en) 2016-04-29
HK1203949A1 (en) 2015-11-06
LT3133073T (lt) 2018-06-25
TR201808088T4 (tr) 2018-06-21
JP5747137B2 (ja) 2015-07-08
CN107915728B (zh) 2021-04-30
HUE037760T2 (hu) 2018-09-28
RS57438B1 (sr) 2018-09-28
LT2800749T (lt) 2016-10-25
US20220211797A1 (en) 2022-07-07
DK3133073T3 (en) 2018-06-18
RU2016124658A (ru) 2018-12-04
EP3133073A2 (en) 2017-02-22
IL233386A (en) 2016-08-31
PL2800749T3 (pl) 2017-01-31
US9586991B2 (en) 2017-03-07
SI3133073T1 (en) 2018-06-29
IL242314A (en) 2016-08-31
PH12015501038A1 (en) 2015-09-21
BR112014016637A8 (pt) 2017-07-04
ZA201405535B (en) 2017-08-30
ME02526B (me) 2017-02-20
PH12014501534B1 (en) 2014-10-08
PH12015501038B1 (en) 2015-09-21
US20130172264A1 (en) 2013-07-04
EP3133073A3 (en) 2017-03-22
IL233386A0 (en) 2014-08-31
KR20150065960A (ko) 2015-06-15
JP2015199738A (ja) 2015-11-12
CL2014001770A1 (es) 2015-04-17
RS55327B1 (sr) 2017-03-31
CA2861637C (en) 2017-07-18
HRP20180976T1 (hr) 2018-08-10
PL3133073T3 (pl) 2018-09-28
EP2800749B1 (en) 2016-09-21
KR101553792B1 (ko) 2015-09-16
MY178390A (en) 2020-10-12
CN104159897A (zh) 2014-11-19
PE20142182A1 (es) 2015-01-16
ME03084B (me) 2019-01-20
US20190224269A1 (en) 2019-07-25
AR123542A2 (es) 2022-12-14
ES2672809T3 (es) 2018-06-18
RU2016124658A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-09-09
JP2015504072A (ja) 2015-02-05
AU2013202780A1 (en) 2013-07-18
NO2755614T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-03-31
US11963994B2 (en) 2024-04-23
SMT201800352T1 (it) 2018-09-13
CN107915728A (zh) 2018-04-17
RU2593259C2 (ru) 2016-08-10
BR112014016637A2 (pt) 2017-06-13
US20170136084A1 (en) 2017-05-18
TW201333001A (zh) 2013-08-16
MX2014007895A (es) 2015-03-19
PT2800749T (pt) 2016-10-24
SI2800749T1 (sl) 2016-11-30
US9238675B2 (en) 2016-01-19
KR101855566B1 (ko) 2018-05-04
PH12014501534A1 (en) 2014-10-08
AR089623A1 (es) 2014-09-03
BR112014016637B1 (pt) 2022-06-14
KR20140107670A (ko) 2014-09-04
US20160102119A1 (en) 2016-04-14
SG11201403784QA (en) 2014-08-28
US20140235551A1 (en) 2014-08-21
CR20140367A (es) 2015-02-18
KR20180051646A (ko) 2018-05-16
PT3133073T (pt) 2018-06-18
US8716236B2 (en) 2014-05-06
TWI503318B (zh) 2015-10-11
HUE031305T2 (hu) 2017-07-28
WO2013103703A1 (en) 2013-07-11
RU2014130171A (ru) 2016-02-27
MA35895B1 (fr) 2014-12-01
AU2013202780B2 (en) 2015-04-16
EP3133073B1 (en) 2018-05-02
RU2728789C2 (ru) 2020-07-31
US11096982B2 (en) 2021-08-24
DK2800749T3 (en) 2016-11-07
MX336294B (es) 2016-01-14
CA2861637A1 (en) 2013-07-11
CY1118371T1 (el) 2017-06-28
CY1120355T1 (el) 2019-07-10
HRP20161381T1 (hr) 2016-12-02
ES2594856T3 (es) 2016-12-23
SMT201600357B (it) 2016-11-10
EP2800749A4 (en) 2015-08-05
KR101917992B1 (ko) 2018-11-13
EP2800749A1 (en) 2014-11-12
UA114417C2 (uk) 2017-06-12

Similar Documents

Publication Publication Date Title
CR20140367A (es) Inhibidores de iap
UY34648A (es) Amidas como inhibidores de pim
MX356368B (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
BR112015011830A2 (pt) compostos e seus métodos de utilização
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
EA201400178A1 (ru) Лечение рака молочной железы
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
CR20150133A (es) Amino-quinolinas como inhibidores de cinasa
DOP2015000060A (es) Profármacos de aminoquinazolina inhibidora de cinasa
CR20150211A (es) Compuestos diméricos
MX2015003909A (es) Antiandrogenos para el tratamiento del cancer de prostata resistente a la castracion no metastasico.
UY34070A (es) Método y composición para tratamiento de semillas.
MX369290B (es) Inhibidores de fbx03.
UY34043A (es) Isoxazolinas como agentes terapéuticos
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
CR20150148A (es) Azaindolinas
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку